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OBJECTIVE—To study how tolerance to GAD65 affects the
development of autoimmunity to other -cell autoantigens (-
CAAs) in GAD65-transgenic (GAD-tg) NOD mice.
RESEARCH DESIGN AND METHODS—We used ELISPOT to
characterize the frequency and functional phenotype of T-cell
responses to GAD65 and other -CAAs at different ages in
GAD-tg mice and their NOD mouse littermates.
RESULTS—In young GAD-tg mice, Th1 responses to GAD65’s
dominant determinants were 1318% of those in young NOD
mice. This coincided with a great reduction in Th1 responses to
other -CAAs. Evidently, GAD65-reactive T-cells are important
for activating and/or expanding early autoreactivities in NOD
mice. As GAD-tg mice aged, their T-cell responses to GAD65
remained low, but they developed supernormal splenic and
pancreatic lymph node T-cell autoimmunity to other -CAAs.
Apparently, the elimination/impairment of many GAD65-reactive
T-cells allowed other -CAA–reactive T-cells to eventually ex-
pand to a greater extent, perhaps by reducing competition for
antigen-presenting cells, or homeostatic proliferation in the
target tissue, which may explain the GAD-tg mouse’s usual
disease incidence.
CONCLUSIONS—Transgenically induced reduction of GAD65
autoreactivity curtailed the development of early T-cell responses to
other -CAAs. However, later in life, -CAA–reactive T-cells
expanded to supernormal levels. These data suggest that early
-cell autoreactivities are mutually dependent for support to
activate and expand, while later in the disease process,
autoantigen-speciﬁc T-cell pools can expand autonomously.
These ﬁndings have implications for understanding type 1
diabetes immunopathogenesis and for designing antigen-based
immunotherapeutics. Diabetes 58:2843–2850, 2009
T
he role of T-cell autoreactivity to the 65-kDa
form of GAD (GAD65) in the etiology of type 1
diabetes in nonobese diabetic (NOD) mice has
been much debated, in large part due to diver-
gent results from different studies of GAD65-tolerized
mice. The early induction of passive tolerance to GAD65
by intravenous antigen injection of 3- to 4-week-old NOD
mice prevented the development of spontaneous T-cell
autoimmunity to -CAAs, insulitis, and type 1 diabetes (1).
Intrathymic injection of GAD65 at 3–4 weeks of age also
prevented type 1 diabetes in NOD mice (2,3), and intrathy-
mic administration of different GAD65 peptides retarded
or accelerated disease onset in NOD mice, depending on
the peptide (3,4).
Using a transgenic approach, Baekkeskov and colleagues
(5) generated GAD65-deﬁcient NOD mice and observed
that these mice had the usual incidence of type 1 diabetes.
This result is difﬁcult to interpret because mouse -cells
express both GAD65 and GAD67 (6), which share great
amino acid sequence identity (7), and T cross-reactivity
occurs between GAD65 and GAD67 (8,9). In addition,
eliminating GAD65 expression may have 1) changed -cell
metabolism, since the GABA produced by GAD65 can
enter the Krebs cycle, or 2) reduced -cell secretion of
GABA, which could have promoted disease progression,
since T-cells possess GABA receptors and GABA inhibits
type 1 diabetes in NOD mice (10,11). In another transgenic
study, Yoon et al. (12) found that antisense-mediated
reduction of both GAD65 and GAD67 speciﬁcally in the
-cells of NOD mice prevented type 1 diabetes and pro-
tected islet grafts from destruction in newly diabetic NOD
mice. Hayday and colleagues (13) used a major histocom-
patibility complex class I (MHCI) promoter to widely
express GAD65 in newborn and adult NOD mice. This,
however, did not establish GAD65 tolerance, and there
was no change in disease incidence. Our recent studies
have shown that GAD65-transgenic mice (GAD-tg mice),
which have an MHC class II (MHCII) promoter construct
driving GAD65 expression in APCs, developed great toler-
ance to GAD65, but their type 1 diabetes incidence was
similar to that of wild-type NOD mice (14). Hence, the
impact of tolerance to GAD65 on the development of T-cell
autoimmunity and type 1 diabetes in NOD mice remains
controversial.
We were interested in whether GAD65 tolerance in the
GAD-tg mice (14) altered the speciﬁcity, frequency, func-
tional phenotype, or timing of autoimmune responses.
Theoretically, the MHCII promoter–driven expression of
GAD65 in their professional APCs should lead to the
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tion or to their functional impairment. High levels of
GAD65 presentation by APCs could have also promoted
antigen-speciﬁc Th2 responses. Additionally, previous
studies have observed that induction of tolerance to an
autoantigen’s dominant determinants can enhance autore-
activity to its subdominant and cryptic determinants (15–
17). Such neoautoreactivities would have been difﬁcult to
detect by testing for T-cell responses to whole GAD65
(14), since subdominant determinants are not well pre-
sented from whole antigen and T-cell responses to cryptic
determinants can only be detected using short synthetic
peptides containing the determinant (18). Therefore, ques-
tions remain concerning the dynamics and speciﬁcity of
spontaneous T-cell responses to GAD65 in GAD-tg mice.
We were also interested in whether tolerance to GAD65
affected the development of T-cell autoreactivities to
other -CAAs. If autoimmunity to GAD65 was important
in type 1 diabetes development in NOD mice, elimina-
tion of GAD65-reactive T-cells should impair the devel-
opment and expansion of T-cell autoreactivities to other
-CAAs. However, the observation that GAD-tg mice
develop type 1 diabetes with the same kinetics as NOD
mice suggests that the elimination of GAD65-reactive
T-cells may have had little impact on the development of
T-cell responses to other -CAAs.
We characterized spontaneous T-cell responses to whole
GAD65, to peptides containing GAD65’s dominant and
cryptic determinants, and to other major -CAAs at early
and late stages of the autoimmune process in GAD-tg and
wild-type NOD mice. We found that spontaneous Th1
responses to GAD65 and its dominant determinants were
greatly reduced, but still present, in GAD-tg mice, without
shifting of GAD65 autoreactivity toward the Th2 pheno-
type or toward GAD65’s cryptic determinants. Interest-
ingly, young GAD-tg mice had signiﬁcantly decreased
T-cell autoreactivities to other -CAAs, indicating that
GAD65 autoreactivity plays a role in the early activation/
expansion of other -CAA–reactive T-cells. Surprisingly,
although older GAD-tg mice continued to have low levels
of T-cell responses to GAD65, they had supernormal
spontaneous splenic and pancreatic lymph node (PLN)
Th1 cell responses to other -CAAs, suggesting that dele-
tion/inactivation of many GAD65-reactive T-cells provided
an opportunity for other -CAA–reactive T-cells to even-
tually expand to a greater extent. We discuss the implica-
tions of these observations for understanding the type 1
diabetes disease process and for designing antigen-based
therapies.
RESEARCH DESIGN AND METHODS
GAD-tg mice were generated by microinjecting NOD mouse oocytes with a
DNA construct consisting of an MHCII enhancer/invariant chain promoter
linked to a mouse GAD65 cDNA (14). The GAD-tg mice were bred with
NOD mice (Jackson Labs), producing GAD-tg offspring that were heterozy-
gous for the transgene or that were nontransgenic NOD mice. The presence
of the transgene was detected by PCR analysis of tail DNA (14). Mice were
maintained under speciﬁc pathogen-free conditions.
Antigens. Mouse GAD65 was puriﬁed as previously described (1). The
autoantigenic and immunodominant GAD65 peptides that were tested in-
cluded GAD(524–543) (also termed GADp35; SRLSKVAPVIKARMMEYGTT),
GAD(217–236) (also termed GADp15; EYVTLKKMREIIGWPGGSGD) (1,19,20),
and GAD(206–220) (TYEIAPVFVLLEYVT) (21). Two peptides containing
“absolute” GAD65 cryptic determinants, which are immunogenic but ignored
by the spontaneous autoimmune response in NOD mice, were also tested:
GAD(260–279) (also known as GADp18, PEVKEKGMAALPRLIAFTSE) and
GAD(398–420) (also known as GADp27, VPLQCSALLVREEGLMONCNQ)
(22). Peptides from other key -cell autoantigens included the immuno-
dominant peptide of the 65-kDa heat shock protein, termed HSPp277
(VLGGGCALLRCIPALDSLTPANED) (23) and insulin B-chain (Sigma) (22–26).
An immunogenic hen egg lysozyme (HEL) peptide (11–25), AMKRHGLDNYR-
GYSL (27), was used as a control foreign peptide. Mouse myelin basic protein
(MBP) (Sigma) was further puriﬁed as previously described (28) and used as
a control self-antigen not involved in the autoimmune response. All peptides
were synthesized by Bio-Synthesis (Lewisville, TX) at 95% purity. Islet lysate
was prepared by brief sonication of isolated islets from NOD.scid mice.
Preparation of mononuclear cells. Splenic mononuclear cells were pre-
pared as in our past studies (29). PLN mononuclear cells were prepared
as previously described (30,31). Brieﬂy, pancreata from individual NOD or
GAD-tg mice at the indicated ages were removed and digested with collage-
nase and DNase I. Pancreatic lymph nodes were obtained by hand picking.
Mononuclear cells were isolated and counted, and only preparations with
95% viability were used.
ELISPOT analysis. The frequency of antigen-speciﬁc interferon (IFN)-–,
interleukin (IL)-4–, and IL-5–secreting T-cells was determined using a modi-
ﬁed ELISPOT technique and optimal antigen concentrations as previously
described (29,32,33). Brieﬂy, 10
6 splenic mononuclear cells or 10
4 PLN
mononuclear cells from individual mice together with 10
6 irradiated (3,000
rads) splenic mononuclear cells were added to individual wells in duplicate in
an ELISPOT plate that had been coated with cytokine capture antibodies and
incubated with peptide (20 mol/l), GAD65 (100 g), or islet lysate (from 40
islets) overnight for IFN- or 40 h for IL-4 and IL-5 detection. After washing,
biotinylated detection antibodies were added and the plates were incubated at
4°C overnight. Bound secondary antibodies were visualized using horseradish
peroxidase–streptoavidin (DAKO) and 3-amino-9-ethylcarbazole. Antibodies
R4-6A2/XMG 1.2-biotin, 11B11/BVD6-24G2-biotin, and TRFK5/TRFK4-biotin
(PharMingen) were used for capture and detection of IFN-, IL-4, and IL-5,
respectively. All assays were done in duplicate or triplicate, and data are from
two to three independent experiments.
Diabetes assessment. After 12 weeks of age, GAD-tg and control NOD mice
were monitored weekly for the development of diabetes by testing their blood
glucose levels. Two consecutive levels of blood glucose 250 mg/dl was
considered onset of diabetes.
Statistical analysis. Data are presented as means  SEM. The difference
between GAD-tg and wild-type NOD mice was statistically analyzed by
Student’s t test. A P value 0.05 was considered statistically signiﬁcant.
RESULTS
GAD-tg and their nontransgenic NOD mouse litter-
mates have similar incidence of type 1 diabetes in our
colonies. Because the environment can affect type 1
diabetes incidence in NOD mice, we examined the kinetics
of type 1 diabetes development in the newly established
GAD-tg mouse colony at the University of California Los
Angeles. As in the previous study of GAD-tg mice (14), we
observed that GAD-tg mice and their nontransgenic NOD
mouse littermates developed type 1 diabetes at similar
rates (Fig. 1), although the onset of type 1 diabetes was
somewhat delayed in our mice relative to the previous
study.
GAD-tg mice develop spontaneous and weak Th1
responses to GAD65. We analyzed the functional pheno-
type and frequency of antigen-speciﬁc autoreactive T-cell
responses to GAD65 in GAD-tg mice and their NOD
littermates directly ex vivo by an ELISPOT assay. Previous
studies have shown that Th1 responses to GAD65 are
detected in the spleen of 3- to 4-week-old NOD mice, and
T-cell autoimmunity to insulin B-chain and HSPp277
become detectable after 6–8 weeks of age (1,2,29). We
therefore examined T-cell responses to these autoantigens
in 8-week-old GAD-tg mice, by which time T-cell responses
to GAD, HSPp277, and insulin B-chain should have been
well established. We detected an average frequency of
159/10
6 IFN-–secreting splenic mononuclear cells T-cells
reactive to whole GAD65 in NOD mice (Fig. 2A), consis-
tent with previous studies (1,20,29). In GAD-tg mice, the
frequency of splenic GAD65-reactive IFN-–secreting T-
cells was reduced to 12/10
6 (8% of that in age-matched
NOD mice) (Fig. 2A), similar to the previous assessment of
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recall response testing (14).
We did not detect any IL-4– or IL-5–secreting splenic
T-cells responding to GAD65 in NOD mice, consistent with
previous studies (20,29); we also did not detect any IL-4 or
IL-5 responses in the spleens of GAD-tg mice (data not
shown). These data suggest that expression of GAD65 in
professional APCs did not shift the functional phenotype
of spontaneous T-cell autoreactivities to GAD65.
Characterization of autoreactivity to dominant and
cryptic GAD65 determinants in GAD-tg mice. GAD65
expression by professional APCs in GAD-tg mice should
enforce passive tolerance to the dominant determinants of
GAD65 that are well presented after antigen processing.
Previous studies have shown that induction of passive
tolerance to a dominant determinant of a -cell autoanti-
gen can enhance T-cell responses to its subdominant and
cryptic determinants (15), which can be detected by
testing T-cell responses to antigenic peptides, since the
determinants are poorly presented from whole protein
(18).
We tested whether expression of GAD65 in profes-
sional APCs modulated spontaneous T-cell responses to
GAD65 antigenic peptides containing dominant determi-
nants GAD(524–543), GAD(217–236), and GAD(206–220)
(1,20,21,29,34) and two “absolute” cryptic determinants
GAD(260–279) and GAD(398–420), which are immuno-
genic but ignored by spontaneous autoimmune responses
in NOD mice (22). We found that the frequency of IFN-–
secreting T-cells recognizing GAD(524–543), GAD(206–
220), and GAD(217–236) in 8-week-old GAD-tg mice were
reduced to 14, 13, and 18%, respectively, of that detected in
the spleens of NOD mouse littermates (Fig. 2B). It is likely
that some T-cell responses also remain to many other
GAD65 autoantigenic determinants that we did not test.
We did not detect IL-4 and IL-5 responses to the GAD65
peptides (data not shown), again suggesting that increased
presentation of the dominant/subdominant determinants
did not alter the functional phenotype of their cognate
effectors. We also did not detect T-cell responses to
GAD65 cryptic determinants in NOD mice, consistent with
previous observations (22), nor in GAD-tg mice (Fig. 2B).
Thus, in contrast to observations in studies of other -cell
autoantigens (35), induction of passive tolerance to
GAD65’s dominant determinants did not enhance T-cell
autoimmunity to its cryptic determinants in our experi-
mental system.
Autoreactivities to other -cell autoantigens are re-
duced in young GAD-tg mice. We next examined the
impact of reduced GAD65 autoimmunity on the develop-
ment of T-cell autoreactivities to the immunodominant
determinants of other -CAAs, namely, insulin B-chain and
HSPp277, in young GAD-tg mice. While we detected fre-
quent splenic IFN-–secreting T-cell responses to insulin
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FIG. 1. GAD-tg and nontransgenic NOD mouse littermates have similar
incidence of diabetes in our colonies at the University of California Los
Angeles. GAD-tg mice, n  10; NOD mice, n  11.
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FIG. 2. Reduced Th1 responses to GAD65 and its dominant determi-
nants without spreading of autoreactivity to its cryptic determinants
or induction of Th2 responses. A: The frequency of IFN-–, IL-4–, and
IL-5–secreting T-cells responding to whole GAD65 in the spleen of
8-week-old GAD-tg and nontransgenic NOD mouse littermates was
analyzed directly ex vivo by ELISPOT assays. The mean number of
IFN-–secreting spot-forming cells (SFCs)  SEM per million spleen
cells is shown. We did not detect any IL-4– or IL-5–secreting splenic
T-cells responding to GAD65 in the spleens of NOD or GAD-tg mice
(data not shown). B: The frequency of IFN-–secreting splenic T-cells
responding to peptides containing dominant determinants GAD(524–
543), GAD(217–236), and GAD(206–220), as well as “absolute” cryptic
determinants GAD(60–279) and GAD(398–420), which are immuno-
genic but ignored by the autoimmune response (22) and control
peptide HEL (11–25). We did not detect IL-4 responses to these
peptides (data not shown). Data shown are averages from four to ﬁve
mice individually analyzed in duplicate in two separate experiments.
Background averaged one SFC in cultures stimulated with control
HEL11–25 or medium alone.
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sponses to insulin B-chain and HSPp277 in the spleen and
PLN of age-matched GAD-tg mice were signiﬁcantly re-
duced. For example, splenic T-cell responses to HSPp277
and insulin B-chain were 14 and 56% of those, respectively,
in NOD mice (P  0.01 for both, Fig. 3A and B). Moreover,
splenic and PLN responses to islet lysate were also signif-
icantly reduced (P  0.05 for both). The responses to islet
lysate were not as greatly reduced as those to HSPp277
and insulin B-chain. This may be because the islet lysate is
comprised of thousands of whole proteins each at different
concentrations such that -CAAs are not at their optimal
concentrations for ELISPOT detection. In contrast, the
insulin B-chain and HSPp277 peptides contain a major
autoantigenic determinant, are readily presented, and are
at an optimal concentration in the ELISPOT assay, provid-
ing a more sensitive readout. We did not detect IL-4– and
IL-5–secreting splenic T-cells responding to GAD, insulin
B-chain, or HSPp277, as in previous studies (28,29) (data
not shown) in either strain of mouse. As expected, T-cell
responses to control MBP were at background levels in the
spleen and PLN. We did not test even younger GAD-tg
mice for T-cell responses to insulin B-chain and HSPp277,
as previous studies have shown that these responses ﬁrst
arise in NOD mouse spleen at 6–8 weeks of age (1,2,20).
Thus, induced passive tolerance to GAD65 curtailed the
early activation and expansion of autoreactive Th1 cells
responding to other -CAAs in GAD-tg mice. The reduced
T-cell autoreactivities to -CAAs in young GAD-tg mice
suggests that at early stages of the disease process,
activated -CAA–reactive T-cells are interdependent for
support to activate and expand.
Enhanced T-cell autoreactivities to other -CAAs in
older GAD-tg mice. The signiﬁcantly reduced T-cell
autoimmunity to -CAAs in young GAD-tg mice was
enigmatic, since GAD-tg mice develop type 1 diabetes at
the same rate as NOD mice. We therefore examined T-cell
autoreactivities to -CAAs at later stages of the disease
process in GAD-tg mice. We found that at 12 weeks of age,
the frequency of IFN-–secreting T-cells responding to
GAD65 in the spleen and PLN remained at low levels (Fig.
4A and B). However, in contrast to the reduced levels of
T-cell autoreactivities to HSPp277 and insulin B-chain
in young GAD-tg mice, we observed signiﬁcantly higher
levels of T-cell autoreactivity to HSPp277 and insulin
B-chain in older GAD-tg mice. At 12 weeks of age, splenic
T-cells responding to HSPp277 and insulin B-chain in
GAD-tg mice were on average 137 and 121% more frequent,
respectively, than in their NOD mouse littermates (P 
0.05 for both) (Fig. 4A). Signiﬁcantly greater Th1 re-
sponses to insulin B-chain and HSPp277 were also ob-
served in the spleen of 16-week-old GAD-tg mice (P  0.01
and 0.05, respectively) (Fig. 4C). Therefore, induction of
tolerance to GAD65 led to supernormal frequencies of
-CAA–reactive T-cells in the spleen of older GAD-tg mice.
Importantly, T-cell autoimmunity to other -CAAs was
also expanded in the PLN of GAD-tg mice. At 12 weeks of
age, PLN T-cell responses against insulin B-chain had
expanded to a greater extent than observed in the spleen
and were on average 202% more frequent than those in the
PLN of their NOD mouse littermates (P  0.01) (Fig. 4B).
The T-cell responses against HSPp277 in the PLN popula-
tion of GAD-Tg mice were increased by 131% (P  0.01). At
16 weeks of age, supernormal T-cell responses were again
observed in the PLN, with responses to insulin B-chain and
HSPp277 166 and 133%, respectively, greater than those in
NOD mice (P  0.01 and 0.05, respectively) (Fig. 4D). We
did not detect IL-4 and IL-5 T-cell responses to these
-CAAs (data not shown). Thus, while partial GAD65
tolerization initially impaired the activation and expansion
of autoreactive T-cells recognizing other -CAAs, it led to
supernormal T-cell autoreactivities to other -CAAs in the
spleen and PLN later in the disease process.
We also analyzed spleen and PLN T-cell responses to an
islet lysate from NOD.scid mice. While these responses
were signiﬁcantly reduced in 8-week-old GAD-tg mice, in
both 12- and 16-week-old GAD-tg mice the frequency of
spleen and PLN IFN-–secreting T-cell responses to the
islet lysate increased to essentially the same level as that
in their age-matched NOD mouse littermates (Fig. 4). This
may explain why the ectopic GAD65 expression in APCs
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FIG. 3. Autoreactivities to -CAAs are reduced in young GAD-tg mice.
The frequency of splenic (A) IFN-–secreting T-cell responses to
HSPp277, insulin B-chain, MBP, and islet lysate in 8-week-old GAD-tg
mice were reduced relative to their nontransgenic NOD mouse litter-
mates. (B) PLN responses to HSPp277, insulin B-chain, and islet lysate
were also signiﬁcantly reduced in GAD-tg mice. We did not detect IL-4–
or IL-5–secreting splenic T-cells responding to these antigens in either
strain of mouse (data not shown). No T-cell responses were detected in
either organ to control MBP. The mean number of IFN-–secreting
SFC  SEM per 10
6 spleen cells, or per 10
4 PLN mononuclear cells, is
shown. *P < 0.05, **P < 0.01.
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mice.
DISCUSSION
Our characterization of T-cell autoreactivities in NOD
GAD-tg mice, which ectopically express GAD65 in profes-
sional APCs, revealed unexpected changes in the dynam-
ics of their autoimmune responses. We observed that in
GAD-tg mice, autoimmune responses to whole GAD65 at 8,
12, and 16 weeks of age were 8–10% of those in age-
matched NOD mouse littermates and that both strains
of mice had similar rates of type 1 diabetes incidence,
consistent with the initial characterization of these mice
(14). T-cell responses to peptides containing GAD65 dom-
inant determinants [GAD(524–543), GAD(206–220), and
GAD(217–236)] were somewhat stronger, ranging from 13
to 18% of those in age-matched NOD mice. The detection
of more frequent Th1 cell responses to synthetic peptides
of GAD65 was likely due to circumventing whole antigen
processing and using optimal peptide concentrations in
our in vitro ELISPOT assays. Since GAD65 is a fairly large
protein with many autoantigenic determinants that we did
not test, the total remaining T-cell responses to GAD65
determinants in these mice is still substantial. Accord-
ingly, it is not possible to draw conclusions from these
mice as to whether GAD65 autoreactivity is required for
the pathogenesis of type 1 diabetes. However, the
reduced responses to other -CAAs in young GAD-tg
mice demonstrate that GAD65-reactive T-cells play an
important role in activating or expanding early -cell
autoreactivities.
In contrast to another study of passive tolerance (15),
we did not detect shifting of T-cell autoreactivity to cryptic
determinants of GAD65 in GAD-tg mice. We also did not
observe the induction of GAD65-speciﬁc Th2 responses.
Thus, the increased presentation of GAD65 by GAD-tg
APCs did not alter the determinant recognition pattern of
spontaneous T-cell responses to GAD65 or the T-cell’s
functional phenotype.
Despite the transgenic expression of GAD65 by profes-
sional APCs to enforce passive tolerance to GAD65, some
cognate T-cells, presumably those with low avidity, es-
caped negative selection and were spontaneously acti-
vated before the mice were 8 weeks of age. Another study
showed that GAD65 expression under the control of an
MHCI promoter was unable to induce tolerance to GAD65
(13). Young preautoimmune NOD mice have a large pool
of high-avidity GAD65-reactive precursor T-cells (29). To-
gether, these observations indicate that GAD65 has limited
impact on T-cell selection during the development and
maturation of NOD mouse T-cells and that even when
extraordinary efforts are taken to ectopically express
GAD65 in a manner expected to delete/anergize cognate
T-cells in transgenic mice, it is difﬁcult to establish com-
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FIG. 4. Enhanced autoreactivities to other -CAAs in older GAD-tg mice. The frequency of T-cell responses to HSPp277, insulin B-chain, MBP,
and islet lysate were tested at 12 weeks of age (A and B) and at 16 weeks of age (C and D) in the spleen (A and C) and PLN (B and D) of GAD-tg
mice and age-matched NOD mouse littermates. While the frequency of T-cells responding to whole GAD65 remained greatly reduced in GAD-tg
mice, splenic T-cell responses to HSPp277 and insulin B-chain were signiﬁcantly increased at 12 weeks of age, as were PLN T-cell responses. T-cell
responses to HSPp277 and insulin B-chain were also supernormal in the spleen and PLN of 16-week-old GAD-tg mice. *P < 0.05, **P < 0.01.
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of remaining cognate T-cells.
In NOD mice, high-avidity GAD65-reactive T-cells are
spontaneously activated at the earliest stages of the auto-
immune process (29). If GAD65-speciﬁc T-cell autoimmu-
nity is a minor component of early autoimmune response,
the elimination or functional impairment of many GAD65-
reactive T-cells in GAD-tg mice should have little impact
on their development of T-cell autoreactivities to other
-CAAs. In contrast to this notion, we observed that in the
spleen and PLN from 8-week-old GAD-tg mice, spontane-
ous Th1 responses were reduced not only to whole GAD65
and peptides containing GAD65’s dominant determinants
but also to HSPp277 and insulin B-chain. For example,
splenic T-cell responses to HSPp277 and insulin B-chain
were 14 and 56%, respectively, of those in age-matched
NOD mice. It is likely that T-cell autoreactivities were also
reduced to other -CAAs that we did not test. Indeed,
T-cell responses to islet lysate were also signiﬁcantly
reduced. Evidently, T-cell responses to GAD65 provide
support for the activation and expansion of T-cell auto-
reactivities to other -CAAs in young NOD mice. In a more
general sense, during the early stages of organ-speciﬁc
autoimmune disease, nascent Th1 autoreactivities to dif-
ferent target tissue antigens may be highly interdependent
for support to further their activation and expansion.
Negative selection purges T-cells that interact too
strongly with self-determinants, leaving T-cells that inter-
act with self-antigens at below-activation thresholds
(36,37). Accordingly, young preautoimmune NOD mice
should have some T-cells that interact with cognate
-CAAs near to their activation threshold (36,37). It is
thought that a wave of -cell apoptosis at about 2 weeks of
age leads to the increased presentation of -CAAs by APCs
in the PLN (38,39). This increased antigen presentation
should theoretically result in the activation of T-cells that
previously interacted with different -CAAs at just below
their activation thresholds. This model predicts that there
should be a simultaneous loss of self-tolerance to many
different -CAAs. Recently, an elegant study of insulin-
tolerant transgenic NOD mice found that these mice have
little or no insulitis and do not develop type 1 diabetes,
suggesting that insulin is the primary target autoantigen
(40). An alternative explanation, consistent with the ob-
servations reported here, is that early T-cell autoreactivi-
ties are interdependent for the expansion of effector
T-cells. Without the usual support from insulin-reactive
T-cells in the insulin-tolerant NOD mice, other -CAA–
reactive effector T-cells that were activated following
-cell remodeling may have succumbed to activation-
induced cell death or they were well controlled by Tregs.
Indeed, T-cells from insulin-tolerant mice efﬁciently trans-
fer type 1 diabetes to NOD.scid mice, albeit more slowly,
demonstrating that effector T-cells do arise in these mice
(40). It remains an open question whether more extensive
tolerance to GAD65 would have prevented the expansion
of autoimmune responses in GAD-tg NOD mice.
Contrasting with the diminished T-cell autoreactivities
to -CAAs in young GAD-tg mice, we observed supernor-
mal autoreactivities to -CAAs in older GAD-tg mice.
Although Th1 responses to GAD65 and its dominant
peptides remained at a low level in older GAD-tg mice, at
12 weeks of age splenic T-cell autoimmunity to HSPp277
and insulin B-chain were 137 and 121%, respectively, and
their PLN responses were 131 and 202%, respectively, of
those in their NOD mouse littermates. A similar pattern
was observed in 16-week-old GAD-tg mice. The increased
Th1 autoimmunity to non-GAD65 -CAAs indicates that
these antigens are well presented by GAD-tg APCs, despite
their ectopic expression of GAD65.
Why do supernormal responses to other -CAAs arise in
older GAD-tg mice? GAD65 contains many autoantigenic
determinants (1,21), and a large pool of high-avidity
GAD65-reactive precursor T-cells are present in preauto-
immune NOD mice (29). Early in the disease process,
when activated autoreactive T-cells are infrequent and the
local inﬂammation is at a low-level, competition for APCs
and room for homeostatic proliferation should not be
limiting factors. As the disease progresses, autoreactive
T-cells become more frequent, and their functional
development and activity require antigen presentation
and costimulation, such that competition for APCs and
space for T-cell expansion may become limiting fac-
tors. Conceivably, the elimination/inactivation of many
GAD65-reactive T-cells in GAD-tg mice removed many
competitors for APCs and provided more room for the
expansion of T-cells that recognize other -CAAs by
homeostatic proliferation in the target tissue (41), partic-
ularly at late stages of the disease process. The greater
opportunity for non–GAD65-reactive T-cells to interact
with APCs and to expand may account for the develop-
ment of supernormal T-cell responses to non-GAD65 auto-
antigens in 12- and 16-week-old GAD-tg NOD mice. T-cell
responses to islet lysate in GAD-tg mice were reduced at 8
weeks of age, but at 12 and 16 weeks of age they increased
to the same level as that in age-matched NOD mice. We
suspect that the “hole” left by eliminating GAD65-reactive
T-cells was ﬁlled-in by other autoreactive T-cells, such that
there was an increase in the frequency of individual
-CAA–speciﬁc T-cell responses without an overall in-
crease in the number of islet lysate-reactive T-cells. The
enhanced autoimmunity to non-GAD65 autoantigens, to-
gether with the normal frequency of Th1 responses to islet
lysate in older GAD-tg mice, may explain why GAD-tg mice
develop type 1 diabetes at a rate similar to that of NOD
mice.
Our observations suggest that during the autoimmune
process, there are two phases of T-cell activation and
expansion: an early phase in which T-cells recognizing
different -CAAs are mutually dependent for activation
and expansion, followed by a later phase in which an
autoantigen-speciﬁc T-cell pool can expand autono-
mously. Early in the autoimmune process, a few T-cells
from different -CAA–reactive T-cell pools activate and
collectively generate a weak proinﬂammatory environ-
ment that is barely sufﬁcient to support further naïve T-cell
activation and activated T-cell expansion. Elimination or
functional impairment of one of the major autoantigen-
speciﬁc pools during this early phase can signiﬁcantly
decrease inﬂammation in the local environment and cur-
tail the activation and expansion of other autoreactive
T-cells. With disease progression, some autoantigen-spe-
ciﬁc T-cell pools have expanded to the point that they can
continue expansion autonomously via positive feedback
mechanisms. Small autoantigen-speciﬁc T-cell pools may
remain reliant on bystander support. The shift of auto-
antigen-speciﬁc effector T-cells from interdependence to
autonomous expansion may be an important feature of the
maturing autoimmune response. In the later autonomous
phase, elimination/impairment of T-cells recognizing one
autoantigen may have little beneﬁcial effect and rather
may promote the activation and expansion of other
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autonomous phase.
We found that inducing passive tolerance to one autoan-
tigen can lead subsequently to enhanced autoreactivities
to other target tissue antigens. This suggests that thera-
peutic strategies based on inducing passive tolerance may
not be very effective for T-cell–mediated autoimmune
diseases. The induction of long-lived regulatory responses
(active tolerance) may be a better therapeutic strategy to
control a diverse autoimmune response (rev. in 42). Many
different -CAA–based immunotherapies that induce reg-
ulatory responses can prevent type 1 diabetes when ad-
ministered to young NOD mice but lose efﬁcacy when
administered later in the disease process (42–45). Their
efﬁcacy in young NOD mice may, in large part, be due to
reducing the local inﬂammation on which -CAA–reactive
T-cells depend for activation and expansion during their
mutual dependence phase. In older NOD mice, the ability
of some autoantigen-speciﬁc T-cell pools to autonomously
expand, together with increased proinﬂammatory by-
stander effects, makes it more difﬁcult for therapy-induced
regulatory T-cells to inhibit disease progression. More-
over, antigen-based therapies prime fewer regulatory re-
sponses in older NOD mice because many cognate T-cells
have already been activated and committed to the autoim-
mune response, reducing the pool of naïve T-cells avail-
able for priming (46). These coinciding effects may help
explain the attenuated efﬁcacy of antigen-based therapeu-
tics as NOD mice mature.
Our studies underscore the dynamic nature of autore-
active T-cell responses and the need to better understand
the immunological impact of antigen-based therapies de-
signed to induce passive or active tolerance. Modulating a
single autoreactive T-cell pool may have complex and
unexpected effects on other autoreactive T-cell responses.
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